Divi's Laboratories reported a turnover of ₹10,388 crore for FY 2025-26. The company also announced its commitment to achieving net-zero GHG emissions by FY 2050, approved by SBTi. Operations at its new Unit 3 facility have commenced.
Divi's Laboratories FY26 Report: Turnover ₹10,388 Cr, Net-Zero by FY50
Turnover: ₹10,388 crore
Net Worth: ₹16,711 crore
Reader Takeaway: Strong turnover and sustainability commitments signal operational growth and environmental responsibility.
What just happened
Divi's Laboratories has released its financial and sustainability update for the fiscal year 2025-26. The company reported a turnover of ₹10,388 crore and a net worth of ₹16,711 crore. As part of its environmental goals, Divi's has committed to achieving net-zero greenhouse gas (GHG) emissions by FY 2050, a target approved by the Science Based Targets initiative (SBTi). The company also commenced operations at its new Unit 3 facility in Kakinada on January 1, 2025.
Why this matters
This update provides investors with key financial performance indicators and highlights the company's strategic focus on sustainability. The significant turnover indicates continued business strength, while the net-zero commitment aligns Divi's with global environmental standards, potentially enhancing its long-term valuation and appeal to ESG-focused investors. The new facility signals expansion and future growth.
The backstory
Divi's Laboratories is a well-established pharmaceutical company known for manufacturing active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company has consistently focused on growth and operational efficiency. Its export contribution of 89% of total turnover underscores its global reach and reliance on international markets.
What changes now
With the commencement of operations at Unit 3, Divi's Laboratories is poised for increased production capacity and potentially higher revenues. The explicit commitment to SBTi-approved net-zero emissions by 2050 signals a long-term strategic shift towards greener operations, which will require sustained investment in renewable energy and waste management technologies.
Risks to watch
While the company reports progress in emissions reduction and waste management, achieving net-zero by 2050 requires continuous innovation and significant capital expenditure. Fluctuations in global demand for APIs and stringent environmental regulations in export markets remain key external risks.
Peer comparison
Many pharmaceutical companies are increasingly focusing on ESG initiatives. Divi's Laboratories' formal commitment to SBTi-approved net-zero targets places it among forward-thinking companies in the sector, though specific emissions reduction figures and water usage metrics should be compared against peers in annual reports.
Context metrics (time-bound)
- Turnover (FY 2025-26): ₹10,388 crore
- Net Worth (FY 2025-26): ₹16,711 crore
- Total Employees (FY 2025-26): 12,119
- Total Workers (FY 2025-26): 7,173
- Export Contribution: 89% of total turnover
- Scope 1 Emissions (FY 2025-26): 3,71,697 Metric tonnes
- Scope 2 Emissions (FY 2025-26): 3,78,516 Metric tonnes
- Water Withdrawal (FY 2025-26): 27,62,689 kiloliters
- GHG Emissions Reduction (FY 2025-26): Approx. 13,500 TCO2e
- Plastic Packaging Waste Reduction (FY 2025-26): Approx. 46 MT
- Unit 3 Kakinada Operations Start: January 01, 2025
- Net-Zero Target: By FY 2050 (SBTi approved)
What to track next
Investors should monitor the financial performance of the new Unit 3 facility, the company's progress in meeting its interim GHG emission reduction milestones, and updates on its renewable energy adoption and waste management initiatives.